Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine

Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute
  • A. SiedlerEmail author
  • J. Koch
  • E. Garbe
  • H. Hengel
  • R. von Kries
  • T. Ledig
  • T. Mertens
  • F. Zepp
  • K. Überla
Bekanntmachungen – Amtliche Mitteilungen

Supplementary material

103_2019_2882_MOESM1_ESM.pdf (791 kb)


  1. 1.
    Siedler A, Koch J, Ultsch B, Garbe E, von Kries R, Ledig T, Mertens T, Überla K, Zepp F, Hengel H (2017) Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany. Bundesgesundheitsbl 60(60):1162–1179Google Scholar
  2. 2.
    German Standing Committee on Vaccination (STIKO) (2011) Standardvorgehensweise (SOP) der Ständigen Impfkommission (STIKO) für die systematische Entwicklung von Impfempfehlungen. . Accessed 28 Mar 2012 (Standard Operating Procedure of the German Standing Committee on Vaccinations (STIKO) for the systematic development of vaccination recommendations) Google Scholar
  3. 3.
    Ständige Impfkommission (STIKO) (2017) Ständige Impfkommission (STIKO). Wissenschaftliche Begründung für die Entscheidung, die Herpes zoster Lebendimpfung nicht als Standardimpfung zu empfehlen. Epid Bull 36:391–410Google Scholar
  4. 4.
    Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E (2015) Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect 70(2):178–186CrossRefPubMedGoogle Scholar
  5. 5.
    Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O (2011) Herpes zoster in Germany: quantifying the burden of disease. Bmc Infect Dis 11:173CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM (2014) Quantification of risk factors for herpes zoster: population based case-control study. BMJ 348. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    European Medicines Agency (EMA) (2018) Summary of product characteristics of Shingrix (herpes zoster vaccine, recombinant, adjuvanted). . Accessed 10 June 2018 Google Scholar
  8. 8.
    Didierlaurent AM, Laupèze B, Di Pasquale A, Hergli N, Collignon C, Garçon N (2017) Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 16(1):55–63CrossRefPubMedGoogle Scholar
  9. 9.
    Glaxo Smith Kline (GSK) (2018) Package leaflet. Shingrix(R), 2018 [updated March 2018; cited 2018 16. . Accessed 17 Oct 2018 Google Scholar
  10. 10.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64(4):380–382CrossRefPubMedGoogle Scholar
  13. 13.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–926CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J et al (2016) Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 375(11):1019–1032CrossRefPubMedGoogle Scholar
  15. 15.
    Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087–2096CrossRefPubMedGoogle Scholar
  16. 16.
    Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH et al (2014) Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 32(15):1745–1753CrossRefPubMedGoogle Scholar
  17. 17.
    Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G et al (2016) Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34(6):863–868CrossRefPubMedGoogle Scholar
  18. 18.
    Pauksens K, Volpe S, Schwarz TF, Smetana J, Toursarkissian N, Rombo L et al (2017) Persistence of Immune Response to an Adjuvanted Varicella—Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults. Open Forum Infect Dis 4(Suppl 1):415CrossRefGoogle Scholar
  19. 19.
    Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF et al (2013) Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults 〉=50 years of age. J Infect Dis 208(12):1953–1961CrossRefPubMedGoogle Scholar
  20. 20.
    EMA Shingrix- EPAR -Assesment report 2018. . Accessed 17 Oct 2018
  21. 21.
    Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C et al (2018) Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study. Vaccine 36(1):148–154CrossRefPubMedGoogle Scholar
  22. 22.
    Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M et al (2017) Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine co-administered with seasonal influenza vaccine in adults aged 50 years and older. J Infect Dis. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Marechal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC et al (2018) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults 〉/=50years of age: A randomized trial. Vaccine 36(29):4278–4286CrossRefPubMedGoogle Scholar
  24. 24.
    Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M et al (2017) Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults 〉/= 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Hum Vaccin Immunother 13(5):1051–1058CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H et al (2017) Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine. J Infect Dis 216(11):1343–1351. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Vink P, Shiramoto M, Ogawa M, Eda M, Douha M, Heineman T et al (2017) Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged 〉/=50 years when administered subcutaneously vs. intramuscularly. Hum Vaccin Immunother 13(3):574–578CrossRefPubMedGoogle Scholar
  27. 27.
    Rogers JE, Cumpston A, Newton M, Craig M (2011) Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis 13(5):480–484CrossRefPubMedGoogle Scholar
  28. 28.
    Schuchter LM, Wingard JR, Piantadosi S, Burns WH, Santos GW, Saral R (1989) Herpes zoster infection after autologous bone marrow transplantation. Blood 74(4):1424–1427PubMedGoogle Scholar
  29. 29.
    Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC et al (2014) A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124(19):2921–2929CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    De la Serna J Efficacy and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients 18 Years of Age or Older: First Results of the Phase 3 Randomized, Placebo-Controlled ZOE-HSCT Clinical Trial. (BMT Tandem Meeting, Salt Lake City, Utah ,21–25 February, 2018)
  31. 31.
    Donahue JG, Choo PW, Manson JE, Platt R (1995) The incidence of herpes zoster. Arch Intern Med 155(15):1605–1609CrossRefPubMedGoogle Scholar
  32. 32.
    Buchbinder SP, Katz MH, Hessol NA, Liu JY, O’Malley PM, Underwood R et al (1992) Herpes zoster and human immunodeficiency virus infection. J Infect Dis 166(5):1153–1156CrossRefPubMedGoogle Scholar
  33. 33.
    Moanna A, Rimland D (2013) Decreasing Incidence of Herpes Zoster in the Highly Active Antiretroviral Therapy Era. Clin Infect Dis 57(1):122–125CrossRefPubMedGoogle Scholar
  34. 34.
    Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M et al (2015) Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 211(8):1279–1287CrossRefPubMedGoogle Scholar
  35. 35.
    Vink P (2017) the Zoster-028 Study G. Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine in Adults with Solid Tumors Vaccinated Before or During Immunosuppressive Chemotherapy Treatment: A Phase II/III, Randomized Clinical Trial. Open Forum Infect Dis 4(Suppl 1):417–S8Google Scholar
  36. 36.
    L Oostvogels. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in Adults with Hematologic Malignancies: A Phase III, Randomized Clinical Trial,. IDWeek, San Diego, CA, USA, . 4–8 October, 2017;Abstract. Google Scholar
  37. 37.
    Vink P (2017) Immunogenicity and Safety of a Candidate Subunit Adjuvanted Herpes Zoster Vaccine (HZ/su) in Adults Post Renal Transplant: a Phase III Randomized Clinical Trial. Open Forum Infect Dis 4(Suppl 1):417Google Scholar
  38. 38.
    Valente N, Lupi S, Stefanati A, Cova M, Sulcaj N, Piccinni L et al (2016) Evaluation of the acceptability of a vaccine against herpes zoster in the over 50 years old: an Italian observational study. BMJ Open 6(10):e11539CrossRefGoogle Scholar
  39. 39.
    Damm O, Witte J, Greiner W (2015) A Systematic Review of Herpes Zoster Vaccine Acceptance. Value Health 18(7):A592CrossRefGoogle Scholar
  40. 40.
    Rieck T, Feig M, Siedler A, Wichmann O (2018) Aktuelles aus der KV-Impfsurveillance – Impfquoten ausgewählter Schutzimpfungen in Deutschland. Epid Bull 01(2018):1–14. CrossRefGoogle Scholar
  41. 41.
    Poethko-Müller C, Schmitz R (2013) Impfstatus von Erwachsenen in Deutschland. Bundesgesundheitsbl 56:845–857. CrossRefGoogle Scholar
  42. 42.
    Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O (2013) Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. Bmc Health Serv Res 13:359CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ultsch B, Weidemann F, Koch J, Siedler A (2017) Projektbericht: Modellierung von epidemiologischen und gesundheitsökonomischen Effekten von Impfungen zur Prävention von Herpes zoster. Robert Koch Institute, Berlin. (Project report: Modeling of epidemiological and health economic effects of vaccinations for the prevention of herpes zoster)
  44. 44.
    Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A et al (2013) Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 14(6):1015–1026CrossRefPubMedGoogle Scholar
  45. 45.
    Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN et al (2010) The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 182(16):1731–1736CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Weisser K, Meyer C, Petzold D, Mentzer D, Keller-Stanislawski B (2007) Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50(11):1404–1417CrossRefPubMedGoogle Scholar
  47. 47.
    Keller-Stanislawski B, Heuss N, Meyer C (2004) Adverse events following immunisation in Germany from 1.1.2001 to 31.12.2003. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47(12):1151–1164CrossRefPubMedGoogle Scholar
  48. 48.
    Siedler A, Rieck T, Reuss A, Walter D, Poggensee G, Poethko-Muller C et al (2012) Estimating vaccination coverage in the absence of immunisation registers—the German experience. Euro Surveill 17(17). CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  • A. Siedler
    • 1
    Email author
  • J. Koch
    • 1
  • E. Garbe
    • 2
  • H. Hengel
    • 3
    • 9
  • R. von Kries
    • 4
  • T. Ledig
    • 5
  • T. Mertens
    • 6
  • F. Zepp
    • 7
  • K. Überla
    • 8
  1. 1.Immunization UnitRobert Koch InstituteBerlinGermany
  2. 2.Bremen Institute for Prevention Research and Social MedicineUniversity of BremenBremenGermany
  3. 3.Institute of Virology, Medical Center–University of FreiburgFaculty of MedicineFreiburgGermany
  4. 4.Institute of Social Paediatrics and Adolescent MedicineLudwig-Maximilians University of MunichMunichGermany
  5. 5.General PracticeDitzingenGermany
  6. 6.Institute of VirologyUlm University Medical CenterUlmGermany
  7. 7.Department of Pediatrics and Adolescent MedicineUniversity Medicine MainzMainzGermany
  8. 8.Institute of Clinical and Molecular VirologyUniversity of Erlangen-NuernbergErlangenGermany
  9. 9.German Consulting Laboratory for HSV and VZVMedical Center – University of FreiburgFreiburgGermany

Personalised recommendations